Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MLC601, also known as NeuroAiD or NeuroAiDTM, is a traditional Chinese medicine-based combination product originally developed to support functional recovery after stroke. It consists of nine herbal components (Radix astragali, Radix salviae miltiorrhizae, Radix paeoniae rubra, Rhizoma chuanxiong, Radix angelicae sinensis, Carthamus tinctorius [safflower], Prunus persica [peach], Radix polygalae [thinleaf milkwort root], and Rhizoma acori tatarinowii [grassleaf sweet flag rhizome]) and five animal-derived components (Hirudo medicinalis [leech], Eupolyphaga seu steleophaga [beetle], Calculus bovis artifactus [artificial cow bezoar], Buthus martensii [scorpion], Cornu saigae tataricae [antelope horn]). The formulation was first registered in China in 2001 and marketed primarily for post-stroke recovery. Preclinical studies suggest neuroprotective and neurorestorative effects through mechanisms such as stimulation of microcirculation, increased cerebral blood flow velocity, promotion of neurogenesis via brain-derived neurotrophic factor (BDNF), cell proliferation, neurite outgrowth, and activation of K ATP channels. Clinical trials have shown mixed results regarding efficacy for acute ischemic stroke; some studies report improved functional outcomes while others show no significant benefit over placebo at 3 months. MLC601 has also been studied for cognitive enhancement in Alzheimer’s disease and traumatic brain injury[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mlc601.